ZUBEREITUNG MIT ROSIGLITAZON UND METFORMIN

Patent europeic · EP1663191 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP1663191
Numer da la dumonda
EP04741403
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
09-08-2004
Publitgà
07-06-2006
Concedì
20-01-2010
Stritgà
31-08-2013
Motiv
Taxa annuala betg pajada
Classas IPC
A61K 31/155 (2006.01)
A61K 31/4439 (2006.01)
A61K 9/28 (2006.01)
A61P 3/10 (2006.01)
Prioritad
GB 0318824 11.08.2003
Dumonda PCT
PCT/EP2004/008970 09.08.2004
Publicaziun PCT
WO2005/013956 17.02.2005
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 19-03-2014

    Stritgà, taxa betg pajada

    Published in Swissreg on 19.03.2014

  2. 20-01-2010

    Concedì

    Published in Swissreg on 20.01.2010

Partidas

Inventur

COLES, Peter John, GlaxoSmithKline Inc.

Mississauga, Ontario L5N 6L4, CA

MACKENZIE, Donald Colin, GlaxoSmithKline (CIDRA)

King of Prussia Pennsylvania 19406, US

MUDD, Paul Norman, Jr., GlaxoSmithKline

Research Triangle Park, NC 27709, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.